These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 38201325)
1. Post-Coronary Artery Bypass Grafting Outcomes of Patients with/without Type-2 Diabetes Mellitus and Chronic Kidney Disease Treated with SGLT2 Inhibitor Dapagliflozin: A Single-Center Experience Analysis. Al Namat R; Duceac LD; Chelaru L; Dabija MG; Guțu C; Marcu C; Popa MV; Popa F; Bogdan Goroftei ER; Țarcă E Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201325 [TBL] [Abstract][Full Text] [Related]
2. Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center. Sugiyama S; Jinnouchi H; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T J Clin Med Res; 2019 Apr; 11(4):267-274. PubMed ID: 30937117 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Kelly MS; Lewis J; Huntsberry AM; Dea L; Portillo I Postgrad Med; 2019 Jan; 131(1):31-42. PubMed ID: 30449220 [TBL] [Abstract][Full Text] [Related]
4. Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting Sardu C; Massetti M; Testa N; Martino LD; Castellano G; Turriziani F; Sasso FC; Torella M; De Feo M; Santulli G; Paolisso G; Marfella R Front Pharmacol; 2021; 12():777083. PubMed ID: 34867407 [No Abstract] [Full Text] [Related]
5. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Xu B; Li S; Kang B; Zhou J Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469 [TBL] [Abstract][Full Text] [Related]
6. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838 [TBL] [Abstract][Full Text] [Related]
7. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905 [TBL] [Abstract][Full Text] [Related]
8. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease. Mima A Adv Ther; 2021 May; 38(5):2201-2212. PubMed ID: 33860925 [TBL] [Abstract][Full Text] [Related]
10. Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology. Hong T; Su Q; Li X; Shan Z; Chen L; Peng Y; Chen L; Yan L; Bao Y; Lyu Z; Shi L; Wang W; Guo L; Ning G; Mu Y; Zhu D Diabetes Metab Res Rev; 2021 May; 37(4):e3416. PubMed ID: 33120435 [TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. Fernandez-Fernandez B; Sarafidis P; Kanbay M; Navarro-González JF; Soler MJ; Górriz JL; Ortiz A Clin Kidney J; 2020 Oct; 13(5):728-733. PubMed ID: 33123352 [TBL] [Abstract][Full Text] [Related]
12. Current Role of Dapagliflozin in Clinical Practice. Zargar AH; Trailokya AA; Ghag S; Pawar R; Aiwale A; Zalke A J Assoc Physicians India; 2021 Sep; 69(9):11-12. PubMed ID: 34585897 [TBL] [Abstract][Full Text] [Related]
13. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes. Vart P; Vaduganathan M; Jongs N; Remuzzi G; Wheeler DC; Hou FF; McCausland F; Chertow GM; Heerspink HJL Clin J Am Soc Nephrol; 2022 Dec; 17(12):1754-1762. PubMed ID: 36414316 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Pharmacokinetics of Dapagliflozin in Patients With Chronic Kidney Disease With or Without Type 2 Diabetes Mellitus. Penland RC; Melin J; Boulton DW; Tang W J Clin Pharmacol; 2023 May; 63(5):551-559. PubMed ID: 36543754 [TBL] [Abstract][Full Text] [Related]
15. The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus. Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T Intern Med; 2018 Aug; 57(15):2147-2156. PubMed ID: 29607968 [TBL] [Abstract][Full Text] [Related]
16. Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial. Satirapoj B; Korkiatpitak P; Supasyndh O Clin Kidney J; 2019 Jun; 12(3):326-332. PubMed ID: 31198224 [TBL] [Abstract][Full Text] [Related]
17. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence. Davidson JA Postgrad Med; 2019 May; 131(4):251-260. PubMed ID: 30929540 [TBL] [Abstract][Full Text] [Related]
18. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease. O'Meara E; Verma S Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364 [TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future? Neuen BL; Jardine MJ; Perkovic V Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i48-i55. PubMed ID: 32003833 [TBL] [Abstract][Full Text] [Related]
20. Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US. Eberly LA; Yang L; Eneanya ND; Essien U; Julien H; Nathan AS; Khatana SAM; Dayoub EJ; Fanaroff AC; Giri J; Groeneveld PW; Adusumalli S JAMA Netw Open; 2021 Apr; 4(4):e216139. PubMed ID: 33856475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]